Dosing and uses of Crisaborole topical
Atopic Dermatitis
Pending FDA approval for mild-to-moderate atopic dermatitis
Pharmacology of Crisaborole topical
Mechanism of action
Phosphodiesterase (PDE)-4 inhibitor; allows for cyclic adenosine monophosphate (cAMP) to remain intact in order to decrease the proinflammatory response (eg, cytokine release) associated with atopic dermatitis
